Stock Update: Bristol-Myers Squibb Company (NYSE:BMY) – Long-Term, 7-Year Study of Nulojix® (belatacept) Regimen Demonstrates Statistically Significant Relative Risk Reduction of Death or Graft Loss over Cyclosporine Regimen in Kidney Transplant

[Business Wire] – Bristol-Myers Squibb Company today announced results from a 7-year, long-term follow-up from a prospective, randomized Phase III trial in kidney transplant patients, which demonstrated a statistically significant 43% relative risk . . . → Read More: Stock Update: Bristol-Myers Squibb Company (NYSE:BMY) – Long-Term, 7-Year Study of Nulojix® (belatacept) Regimen Demonstrates Statistically Significant Relative Risk Reduction of Death or Graft Loss over Cyclosporine Regimen in Kidney Transplant Similar Articles: Stock Update (NYSE:BMY): Bristol-Myers Squibb to Present at Bank of America Merrill Lynch 2015 Health Care Conference Market Update (NYSE:BMY): Bristol-Myers Squibb Announces Cash Tender Offer For Up to $400 Million Aggregate Principal Amount of its Outstanding Debt Securities Stock Update (NYSE:BMY): Bristol-Myers Squibb Signs Exclusive Agreement with Bavarian Nordic for PROSTVAC®, a Prostate-Specific Antigen-Targeting Cancer Immunotherapy